Dihydroorotate dehydrogenase (DHODH) is the fourth enzyme in the de novo pyrimidine biosynthesis pathway, serving as the catalyst to oxidize the dihydroorotate to orotic acid in the biosynthesis of uridine monophosphate (UMP). Both autoimmune diseases and malaria have been known to be affected by DHODH.
DHODHs are divided into two families based on localization and the electron acceptor: While family 2 members are membrane proteins localized to the inner mitochondrial membrane, family 1 members are soluble proteins localized to the cytosol. Families 1A and 1B, which use fumarate and NAD+ as their respective electron acceptors, are further divided into families 1. Respiratory quinones are used by DHODH enzymes in family 2 as electron acceptors.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V67801 | RORγt/DHODH-IN-1 | 2764662-15-7 | RORγt/DHODH-IN-1 (compound (R)-14d) is a potent and orally bioactive dual RORγt/DHODH inhibitor (antagonist) with IC50s of 0.083 μM and 0.172 μM, respectively. |
|
V67802 | RORγt/DHODH-IN-2 | 2641758-86-1 | RORγt/DHODH-IN-2 (compound 1) is a potent dual RORγt/DHODH inhibitor. |
|
V67803 | RORγt/DHODH-IN-3 | 2764662-16-8 | RORγt/DHODH-IN-3 (compound (S)-14d) is a dual RORγt/DHODH inhibitor (antagonist) with IC50s of 0.098 μM and 0.432 μM, respectively. |
|
V72000 | UCK2 Inhibitor-2 | 866842-71-9 | UCK2 Inhibitor-2 is a noncompetitive uridine cytidine kinase 2 (UCK2) inhibitor (antagonist) with IC50 of 3.8 µM. |
|
V71997 | Vidofludimus hemicalcium (4sc-101 hemicalcium; SC12267 hemicalcium) | 1354012-90-0 | Vidofludimus (4sc-101; SC12267) hemicalcium is an orally bioavailable inhibitor of dihydroorotate dehydrogenase (DHODH) and a farnesoid X receptor (FXR) modulator. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
